“Neutralizing Interleukin-13 Increases Skin Microbial Diversity: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Tralokinumab in Adult Patients With Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s56, https://doi.org/10.25251/skin.5.supp.56.